World Library  
  
Flag as Inappropriate
Email this Article

Mexiletine

Article Id: WHEBN0005078002
Reproduction Date:

Title: Mexiletine  
Author: World Heritage Encyclopedia
Language: English
Subject: Sodium channel blocker, Antiarrhythmic agent, Verapamil, Analgesic, Analgesics
Collection: Analgesics, Antiarrhythmic Agents, Local Anesthetics, Phenol Ethers, Sodium Channel Blockers
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Mexiletine

Mexiletine
Systematic (IUPAC) name
(RS)-1-(2,6-dimethylphenoxy)propan-2-amine
OR
2-(2-aminopropoxy)-1,3-dimethylbenzene
Clinical data
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • AU: B1
  • US: C (Risk not ruled out)
Legal status
Routes of
administration 		Oral, IV
Pharmacokinetic data
Bioavailability 90%
Protein binding 50-60%
Metabolism Hepatic (CYP2D6 and 1A2- mediated)
Biological half-life 10-12 hours
Excretion Renal (10%)
Identifiers
CAS Registry Number  Y
ATC code C01
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  Y
ChEMBL  Y
Chemical data
Formula C11H17NO
Molecular mass 179.259 g/mol
 Y   

Mexiletine (INN) (sold under the trade name Mexitil) is a non-selective voltage-gated sodium channel blocker which belongs to the Class IB anti-arrhythmic group of medicines.[1] It is used to treat arrhythmias within the heart, or seriously irregular heartbeats. It slows conduction in the heart and makes the heart tissue less sensitive. Dizziness, heartburn, nausea, nervousness, trembling, unsteadiness are common side effects. It is available in injection and capsule form.

Class IB antiarrhythmics decrease action potential frequency by lengthening the repolarization phase. This is achieved by blocking sodium channels.[2]

This drug is now no longer freely available as a licensed product in either the US or the UK. It can be imported to the UK as an unlicensed, 'named-patient' drug. Its use in arrhythmias is restricted to use in life-threatening conditions only.

Mexiletine may also be of use in patients experiencing refractory pain[3] and is also effective for treating muscle stiffness resulting from myotonic dystrophy (Steinert's disease) or nondystrophic myotonias such as myotonia congenita (Thomsen disease).

Contents

  • Synthesis 1
  • References 2
  • Further reading 3
  • External links 4

Synthesis

Mexiletine synthesis:[4][5][6][7]

References

  1. ^ Sergio Canavero; Vincenzo Bonicalzi (13 October 2011). Central Pain Syndrome: Pathophysiology, Diagnosis and Management. Cambridge University Press. pp. 286–.  
  2. ^ Mexiletine, RxList.com
  3. ^ Sweetman S (ed.) (2002).  
  4. ^ H. Koppe, W. Kummer, U.S. Patent 3,954,872 (1976).
  5. ^ H. Koppe, W. Kummer, U.S. Patent 3,659,019 (1972).
  6. ^ C.H. Boehringer Sohns, Fr 1551055  (1968).
  7. ^ H. Koppe, W. Kummer, U.S. Patent 4,031,244 (1977).

Further reading

  • Peck T; Hill S, Williams M (eds.) (2004). Pharmacology for Anaesthesia and Intensive Care (2nd ed.).  

External links

  • MedlinePlus Drug Information: Mexiletine


Channel blockers
class Ia (Phase 0→ and Phase 3→)
class Ib (Phase 3←)
class Ic (Phase 0→)
Receptor agonists
and antagonists
M2
Ion transporters
Index of the heart
Description
Disease
Treatment
  • Drugs
Monoaminergics
Ion channel blockers
Others


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.